RA Capital puts $175M behind Oak Hill Bio to revive shelved Angelman syndrome drug

RA Capital and a group of investors have committed $175 million to Oak Hill Bio, a startup aiming to revive an Angelman syndrome drug previously shelved by Roche. The company competes with Ultragenyx Pharmaceutical and Ionis Pharmaceuticals, both already in Phase 3 trials for the same rare brain disease. Ultragenyx is expected to publish results this year.